CB1578

CHO-K1 IndCD19/CD22

£9,000.00
£9,000.00
Tax included.
Out of Stock

CHO-K1 IndCD19/CD22 is an IndEx-2 stable cell line inducibly and independently expressing full length human CD19 and CD22.

FOR RESEARCH USE ONLY

Vial labeled 'Rouken Cells' with technical specifications on a white background
Flow cytometry plot showing CD19 expression with induced and non-induced conditions.
Graph showing CD19 induction with varying inducer concentrations, labeled 'CD19 Induction'.
Graph showing CD22 expression with induced and non-induced conditions on a white background
Graph showing CD22 induction with inducer concentration on a log scale
Graph showing CD19 and CD22 induction at different concentrations
  • Vial labeled 'Rouken Cells' with technical specifications on a white background
  • Flow cytometry plot showing CD19 expression with induced and non-induced conditions.
  • Graph showing CD19 induction with varying inducer concentrations, labeled 'CD19 Induction'.
  • Graph showing CD22 expression with induced and non-induced conditions on a white background
  • Graph showing CD22 induction with inducer concentration on a log scale
  • Graph showing CD19 and CD22 induction at different concentrations
Vial labeled 'Rouken Cells' with technical specifications on a white background
Flow cytometry plot showing CD19 expression with induced and non-induced conditions.
Graph showing CD19 induction with varying inducer concentrations, labeled 'CD19 Induction'.
Graph showing CD22 expression with induced and non-induced conditions on a white background
Graph showing CD22 induction with inducer concentration on a log scale
Graph showing CD19 and CD22 induction at different concentrations
Specification
Inducible Receptor
CD19
CD22
CD Designation
CD19
CD22
Gene name
CD19
CD22
Aliases
CD19, B-lymphocyte antigen CD19
CD22, SIGLEC2
Uniprot ID
P15391
P20273
Receptor Species
Homo sapiens
Homo sapiens
Cell Line Background
CHO-K1
Target Information and Further Details
CD19 (Cluster of Differentiation 19) and CD22 (Cluster of Differentiation 22) are highly validated B-cell–restricted immuno-oncology targets that have transformed the treatment landscape of B-cell malignancies. CD19 is a pan–B-cell marker expressed from early B-cell development through most differentiation stages and functions as a key co-receptor that amplifies B-cell receptor (BCR) signalling. Its uniform and high-density expression in malignancies such as B-ALL, CLL, and NHL has made it a cornerstone target for therapies including the CD19×CD3 bispecific T-cell engager blinatumomab and multiple CAR-T products.

CD22, in contrast, acts as an inhibitory BCR co-receptor containing ITIM motifs that recruit phosphatases such as SHP-1 to attenuate activation signalling. It is expressed predominantly on mature B cells and is rapidly internalised upon antibody engagement, a property leveraged in antibody–drug conjugates such as inotuzumab ozogamicin. Importantly, CD22 expression is frequently retained in patients who relapse after CD19-directed therapies. Together, CD19 and CD22 are attractive for bispecific strategies because dual targeting can mitigate antigen escape, a common mechanism of resistance to single-antigen therapies.

The CHO-K1 CD19/CD22 IndEx-2 cell line enables independent, titratable control of both CD19 and CD22 expression providing a powerful system to evaluate binding avidity, cytotoxic thresholds, antigen-density requirements, and synergistic or competitive effects in CD19×CD22 bispecific development.
Performance Data
Flow cytometry plot showing CD19 expression with induced and non-induced conditions.

Figure 1 – Histograms of CD19 Induction at 0-300 µM Inducer 1.

Graph showing CD19 induction with varying inducer concentrations, labeled 'CD19 Induction'.

Figure 2 – Histograms of CD22 Induction at 0-300 µM Inducer 2.

Graph showing CD22 expression with induced and non-induced conditions on a white background

Figure 3 – Quantification of orthogonal CD19 Induction at 0-300 µM Inducer 1.

Graph showing CD22 induction with inducer concentration on a log scale

Figure 4 – Quantification of orthogonal CD22 Induction at 0-300 µM Inducer 2.

Graph showing CD19 and CD22 induction at different concentrations

Figure 5 – Quantification of dual CD19/CD22 Induction at 0-300 µM Inducer 1/Inducer 2.

* Cells were then stained with a labelled antibody and expression levels quantified using a bead-based quantification kit. Specific induction conditions should be further defined by the user. Cell line suitable for preclinical research and development use only.

Shipping Details

Supplied as 1 vial of >3 million viable cells.

* Please note that US import permits for CHO-K1 cell products are the responsibility of the US-based recipient/importer. RoukenCells is happy to provide supporting documentation (e.g. product descriptions and noninfectious statements) to assist with the import process.

Cell Line Datasheet

Access detailed product specifications, user guides and technical documentation in PDF format.

Download PDF

Related products

Take a moment to explore selections tailored just for you.

Explore Now